全文获取类型
收费全文 | 1404篇 |
免费 | 80篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 47篇 |
妇产科学 | 6篇 |
基础医学 | 132篇 |
临床医学 | 65篇 |
内科学 | 66篇 |
皮肤病学 | 6篇 |
神经病学 | 39篇 |
特种医学 | 33篇 |
外科学 | 35篇 |
综合类 | 48篇 |
现状与发展 | 1篇 |
预防医学 | 545篇 |
眼科学 | 5篇 |
药学 | 338篇 |
中国医学 | 11篇 |
肿瘤学 | 120篇 |
出版年
2024年 | 5篇 |
2023年 | 62篇 |
2022年 | 74篇 |
2021年 | 96篇 |
2020年 | 89篇 |
2019年 | 88篇 |
2018年 | 89篇 |
2017年 | 56篇 |
2016年 | 71篇 |
2015年 | 55篇 |
2014年 | 74篇 |
2013年 | 138篇 |
2012年 | 53篇 |
2011年 | 85篇 |
2010年 | 59篇 |
2009年 | 53篇 |
2008年 | 41篇 |
2007年 | 26篇 |
2006年 | 27篇 |
2005年 | 23篇 |
2004年 | 21篇 |
2003年 | 21篇 |
2002年 | 13篇 |
2001年 | 14篇 |
2000年 | 13篇 |
1999年 | 9篇 |
1998年 | 5篇 |
1997年 | 6篇 |
1996年 | 2篇 |
1995年 | 13篇 |
1994年 | 15篇 |
1993年 | 3篇 |
1992年 | 7篇 |
1991年 | 18篇 |
1990年 | 8篇 |
1989年 | 6篇 |
1988年 | 3篇 |
1987年 | 9篇 |
1986年 | 6篇 |
1985年 | 14篇 |
1984年 | 7篇 |
1983年 | 8篇 |
1982年 | 8篇 |
1981年 | 4篇 |
1980年 | 3篇 |
1977年 | 1篇 |
1976年 | 2篇 |
1974年 | 1篇 |
排序方式: 共有1504条查询结果,搜索用时 15 毫秒
51.
Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses
下载免费PDF全文
![点击此处可从《Clinical and experimental immunology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
H. Schaballie G. Wuyts D. Dillaerts G. Frans L. Moens M. Proesmans F. Vermeulen K. De Boeck I. Meyts X. Bossuyt 《Clinical and experimental immunology》2016,185(2):180-189
During the past 10 years, pneumococcal conjugate vaccine (PCV) has become part of the standard childhood vaccination programme. This may impact upon the diagnosis of polysaccharide antibody deficiency by measurement of anti‐polysaccharide immunoglobulin (Ig)G after immunization with unconjugated pneumococcal polysaccharide vaccine (PPV). Indeed, contrary to PPV, PCV induces a T‐dependent, more pronounced memory response. The antibody response to PPV was studied retrospectively in patients referred for suspected humoral immunodeficiency. The study population was divided into four subgroups based on age (2–5 years versus ≥ 10 years) and time tested (1998–2005 versus 2010–12). Only 2–5‐year‐old children tested in 2010–12 had been vaccinated with PCV prior to PPV. The PCV primed group showed higher antibody responses for PCV–PPV shared serotypes 4 and 18C than the unprimed groups. To a lesser extent, this was also found for non‐PCV serotype 9N, but not for non‐PCV serotypes 19A and 8. Furthermore, PCV‐priming elicited a higher IgG2 response. In conclusion, previous PCV vaccination affects antibody response to PPV for shared serotypes, but can also influence antibody response to some non‐PCV serotypes (9N). With increasing number of serotypes included in PCV, the diagnostic assessment for polysaccharide antibody deficiency requires careful selection of serotypes that are not influenced by prior PCV (e.g. serotype 8). Further research is needed to identify more serotypes that are not influenced. 相似文献
52.
The apical conjugate efflux pump ABCC2 (MRP2) 总被引:7,自引:0,他引:7
53.
Wei Jiang Jo A. Wick Jianghua He Jonathan D. Mahnken Matthew S. Mayo 《Journal of biopharmaceutical statistics》2018,28(5):824-839
Frequentist design for two-arm randomized Phase II clinical trials with outcomes from the exponential dispersion family was proposed previously, where the total sample sizes are minimized under multiple constraints on the standard errors of the estimated group means and their difference. This design was generalized from an approach specific for dichotomous outcomes. The two previous approaches measure the central tendency of each group and treatment effect based on mean and difference in means. Other measures such as median or hazard ratio are more appropriate under certain situations. In addition, the frequentist approaches assume that unknown parameters are fixed values. This does not reflect the reality that uncertainty always exists for unknowns. Compared to the frequentist methods, the Bayesian approach offers a flexible way to measure central tendency and treatment effect, and incorporate uncertainty in parameters of interest into considerations. In this article, we generalize a Bayesian design for Phase II clinical trials with endpoints in the exponential family from the two previously developed frequentist approaches. The proposed design minimizes the total sample sizes under pre-specified constraints on the expected length of posterior credible intervals for measures of treatment effect and central tendency in each group. The design is applicable for trials with fixed or optimal randomization allocation ratio and can be applied under adaptive procedure. Examples of method implementations are provided for different types of endpoints from the exponential family in both fixed and adaptive settings. 相似文献
54.
The efficient targeting of drugs to tumor cell and subsequent rapid drug release remain primary challenges in the development of nanomedicines for cancer therapy. Here, we constructed a glucose transporter 1 (GLUT1)-targeting and tumor cell microenvironment-sensitive drug release Glucose–PEG–PAMAM-s-s–Camptothecin-Cy7 (GPCC) conjugate to tackle the dilemma. The conjugate was characterized by a small particle size, spherical shape, and glutathione (GSH)-sensitive drug release. In vitro tumor targeting was explored in monolayer (2D) and multilayer tumor spheroid (3D) HepG2 cancer cell models (GLUT1+). The cellular uptake of GPCC was higher than that in the control groups and that in normal L02 cells (GLUT1?), likely due to the conjugated glucose moiety. Moreover, the GPCC conjugate exhibited stronger cytotoxicity, higher S arrest and enhanced apoptosis and necrosis rate in HepG2 cells than control groups but not L02 cells. However, the cytotoxicity of GPCC was lower than that of free CPT, which could be explained by the slower release of CPT from the GPCC compared with free CPT. Additional in vivo tumor targeting experiments demonstrated the superior tumor-targeting ability of the GPCC conjugate, which significantly accumulated in tumor meanwhile minimize in normal tissues compared with control groups. The GPCC conjugate showed better pharmacokinetic properties, enabling a prolonged circulation time and increased camptothecin area under the curve (AUC). These features contributed to better therapeutic efficacy and lower toxicity in H22 hepatocarcinoma tumor-bearing mice. The GLUT1-targeting, GSH-sensitive GPCC conjugate provides an efficient, safe and economic approach for tumor cell targeted drug delivery. 相似文献
55.
《Vaccine》2018,36(14):1908-1916
BackgroundWe evaluated the immunogenicity and safety of 1 and 2 doses of quadrivalent meningococcal serogroup A, C, W and Y tetanus toxoid-conjugate vaccine (MenACWY-TT) given alone or co-administered with 13-valent pneumococcal conjugate vaccine (PCV13) in toddlers.MethodsIn this phase III, open-label, controlled, multicentre study (NCT01939158), healthy toddlers aged 12–14 months were randomised into 4 groups to receive 1 dose of MenACWY-TT at month (M) 0 (ACWY_1), 2 doses of MenACWY-TT at M0 and M2 (ACWY_2), MenACWY-TT and PCV13 at M0 (Co-ad), or PCV13 at M0 and MenACWY-TT at M2 (PCV13/ACWY). Immune responses were assessed 1 month post-each vaccination. Solicited and unsolicited symptoms were recorded for 4 and 31 days post-each vaccination, respectively; serious adverse events (SAEs) and new onset of chronic illnesses (NOCIs) up to M9 from first vaccination.Results802 toddlers were vaccinated. Post-dose 1 of MenACWY-TT, ≥92.8% of toddlers had rSBA titres ≥1:8, and ≥62.5% had hSBA titres ≥1:4 for each meningococcal serogroup. Post-dose 2 of MenACWY-TT, rSBA titres ≥1:8 were observed in ≥98.0% and hSBA titres ≥1:4 in ≥95.3% of toddlers. Percentages of toddlers with hSBA titres ≥1:4 were higher after 2 doses versus 1 dose of MenACWY-TT for MenW (97.1% versus 62.5–68.9%) and MenY (95.3% versus 64.3–67.6%). Non-inferiority of immune responses to co-administered MenACWY-TT and PCV13 over their separate administration was demonstrated. AEs incidence was comparable among groups. SAEs were reported for 4.9%, 5.1%, 5.5% and 7.5%, and NOCIs for 2.0%, 3.0%, 0.5% and 3.5% of toddlers in the ACWY_1, ACWY_2, Co-ad and PCV13/ACWY groups, respectively; 4 SAEs reported in 3 toddlers were vaccine-related. Two fatal vaccine-unrelated SAEs were reported.ConclusionMenACWY-TT was immunogenic when administered as a single dose at 12–14 months of age. A second dose in toddlers increased hSBA responses against MenW and MenY. MenACWY-TT and PCV13 can be co-administered without impairing the immunogenicity or safety profile of either vaccine. 相似文献
56.
《Vaccine》2018,36(5):698-706
BackgroundTo support vaccination programs in developing countries, a 4-dose vial presentation of pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was developed. This study assessed immunologic non-inferiority and safety of the investigational PHiD-CV 4-dose versus licensed 1-dose vial presentation in infants.MethodsIn this phase III, mono-center, observer-blind study in Bangladesh, 6–10-week-old infants were randomized 1:1 to receive PHiD-CV primary vaccination (at ages 6, 10, 18 weeks) and a booster dose (at age 9 months) with a 4-dose vial (with preservative, 4DV group) or 1-dose vial (preservative-free, 1DV group). DTPw-HBV/Hib was (co)-administered per study protocol and polio, measles and rubella vaccines as part of the national immunization program. Non-inferiority of PHiD-CV 4-dose versus 1-dose vial for each vaccine pneumococcal serotype (VT) and vaccine-related serotype 19A in terms of antibody geometric mean concentration (GMC) was assessed (criterion: upper limit of 2-sided 95% confidence interval of antibody GMC ratios [1DV/4DV] <2-fold). Immune responses were measured. Solicited, unsolicited and serious adverse events (AEs) were evaluated.ResultsOf 320 infants (160 per group) vaccinated during the primary vaccination phase, 297 received a booster. Non-inferiority was demonstrated for each VT and 19A. One month post-primary vaccination, for most VT, ≥97.9% of infants in each group had antibody concentrations ≥0.2 μg/mL; for 19A ≥ 80.1% reached this threshold. Pneumococcal antibody responses and opsonophagocytic activity for each VT and 19A were within similar ranges between groups after primary and booster vaccination, as were anti-protein D responses. Booster immune responses were observed in both groups. Reported AEs were within similar ranges for both presentations.ConclusionImmunologic non-inferiority of PHiD-CV 4-dose vial (with preservative) versus PHiD-CV 1-dose vial (preservative-free) was demonstrated. Immune responses and reactogenicity following primary/booster vaccination were within similar ranges for both presentations. PHiD-CV 4-dose vial would help improve access and coverage in resource-limited countries.Clinical Trial Registry: NCT02447432. 相似文献
57.
《Journal of infection and chemotherapy》2020,26(5):465-470
In November 2013, a 13-valent pneumococcal conjugate vaccine (PCV13) for all infants aged younger than 5 years was incorporated into the Japan national immunization program. An annual survey of nasopharyngeal carriage rates was performed on healthy infants aged 2–24 months from Okinawa, Japan to evaluate the effect of PCV13 on pneumococcal colonization. Of 756 evaluable infants, 203 pneumococcal strains were detected in 193 infants. The overall nasopharyngeal carriage rate was 25.5%, which was not different from our previously reported isolation rate before the introduction of PCV13. The main serotypes of the Streptococcus pneumoniae strains are 15A (18.2%), non-typeable (14.8%), and 15B (11.8%). The carriage rates of pneumococcal strains with 7-valent pneumococcal conjugate vaccine serotypes and PCV13 serotypes were 3.0% and 9.9%, respectively. These values were significantly lower than we reported before the introduction of PCV13. However, the carriage rates of non-PCV13 serotypes have increased. Multivariate logistic regression analysis suggested that siblings and day care attendance are risk factors for pneumococcal carriage. 相似文献
58.
Daniel P. Petrylak MD Nicholas J. Vogelzang MD Kamal Chatta MD Mark T. Fleming MD David C. Smith MD Leonard J. Appleman MD PhD Arif Hussain MD Manuel Modiano MD Parminder Singh MD Scott T. Tagawa MD Ira Gore MD Edward F. McClay MD Anthony E. Mega MD A. Oliver Sartor MD Bradley Somer MD Raymond Wadlow MD Neal D. Shore MD William C. Olson PhD Nancy Stambler DrPH Vincent A. DiPippo PhD Robert J. Israel MD 《The Prostate》2020,80(1):99-108
59.
Large molecule therapeutics (MW > 1000 daltons) are not expected to enter the cell and thus have reduced potential to interact directly with DNA or related physiological processes. Genotoxicity studies are therefore not relevant and typically not required for large molecule therapeutic candidates. Regulatory guidance supports this approach; however there are examples of marketed large molecule therapeutics where sponsors have conducted genotoxicity studies. A retrospective analysis was performed on genotoxicity studies of United States FDA approved large molecule therapeutics since 1998 identified through the Drugs@FDA website. This information was used to provide a data-driven rationale for genotoxicity evaluations of large molecule therapeutics. Fifty-three of the 99 therapeutics identified were tested for genotoxic potential. None of the therapeutics tested showed a positive outcome in any study except the peptide glucagon (GlucaGen®) showing equivocal in vitro results, as stated in the product labeling. Scientific rationale and data from this review indicate that testing of a majority of large molecule modalities do not add value to risk assessment and support current regulatory guidance. Similarly, the data do not support testing of peptides containing only natural amino acids. Peptides containing non-natural amino acids and small molecules in conjugated products may need to be tested. 相似文献
60.
Reinforced concrete (RC) beams are basic elements used in the construction of various structures and infrastructural systems. When exposed to harsh environmental conditions, the integrity of RC beams could be compromised as a result of various deterioration mechanisms. One of the most common deterioration mechanisms is the formation of different types of corrosion in the steel reinforcements of the beams, which could impact the overall reliability of the beam. Existing classical reliability analysis methods have shown unstable results when used for the assessment of highly nonlinear problems, such as corroded RC beams. To that end, the main purpose of this paper is to explore the use of a structural reliability method for the multi-state assessment of corroded RC beams. To do so, an improved reliability method, namely the three-term conjugate map (TCM) based on the first order reliability method (FORM), is used. The application of the TCM method to identify the multi-state failure of RC beams is validated against various well-known structural reliability-based FORM formulations. The limit state function (LSF) for corroded RC beams is formulated in accordance with two corrosion types, namely uniform and pitting corrosion, and with consideration of brittle fracture due to the pit-to-crack transition probability. The time-dependent reliability analyses conducted in this study are also used to assess the influence of various parameters on the resulting failure probability of the corroded beams. The results show that the nominal bar diameter, corrosion initiation rate, and the external loads have an important influence on the safety of these structures. In addition, the proposed method is shown to outperform other reliability-based FORM formulations in predicting the level of reliability in RC beams. 相似文献